论文部分内容阅读
目的研究中国丙型肝炎病毒(HCV)RNA1b基因型的5’NCR一级结构的基因变异。方法对147例HCV1b基因型血清样品进行5’NCR扩增,分别用MboⅠ、BamHⅠ限制性内切酶酶切分析后,与40株HCV1b型全基因株的5’NCR进行比较。结果测序证实中国HCV1b基因型在120位发生变异(CT),在117位产生BamHⅠ酶切位点。147例患者中存在BamHⅠ切点的有17例(1156%)。既无BamHⅠ切点,也无MboⅠ切点的有26例(1769%)。存在2个MboⅠ切点6例(408%)。存在1个MboⅠ切点有80例(5442%)。既有MboⅠ切点,又同时存在无MboⅠ切点的变异株18例(1224%)。结论在147份血清样品中具有1个MboⅠ切点的占5442%,这和干扰素治疗疗效只有50%~60%是否存在联系尚有待于研究。中国HCV1b基因株与40株HCV1b标准株相比,在117位有特异的BamHⅠ酶切位点,这一特异的BamHⅠ切点是否仅在中国丙型肝炎感染者中存在,及其有何生物学意义,尚有待于进一步研究。
Objective To study the gene mutation of 5’NCR primary structure of hepatitis C virus (HCV) RNA1b genotype in China. Methods A total of 147 cases of HCV1b genotypes were amplified by 5 ’NCR and compared with the 5’NCR of 40 HCV1b genotypes by restriction enzyme digestion with Mbo Ⅰ and BamH Ⅰ, respectively. Results Sequencing confirmed that the genotype of HCV1b in China was mutated at position 120 and the BamHI site at position 117. Seventeen patients (1156%) had BamHI sites in 147 patients. There were 26 cases (1769%) with neither BamH I site nor Mbo I site. There were 6 Mbo I sites (408%). There were 1 Mbo I point of interest in 80 cases (5442%). There were 18 cases (1224%) of MboⅠpoint and MboⅠpoint mutation. Conclusions 5442% of the 147 serum samples with one Mbo I site are related to the efficacy of interferon therapy only 50% ~ 60%. Compared with 40 HCV1b standard strains, HCV1b gene in China has a specific BamHI site at 117, whether this specific BamHI site is only found in HCV-infected patients in China and its biological status Meaning, yet to be further studied.